Clinical Trials
53 trialsNCT04158141 2026-05-19
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology
Phase 3 Terminated
NCT01851395 2026-05-05
Rapid Autopsy and Procurement of Cancer Tissue
National Institutes of Health Clinical Center (CC)
Terminated
NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT04166734 2026-02-04
MESO-PRIME
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05047536 2025-12-19
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Terminated
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT06336148 2025-10-15
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Phase 1 Terminated
NCT02613299 2025-07-14
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma
Mayo Clinic
Terminated
NCT04301011 2025-04-23
RAPTOR
Turnstone Biologics, Corp.
Phase 1 Terminated
NCT03975387 2025-04-09
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
Taiho Oncology, Inc.
Phase 1 Terminated
NCT02648763 2025-01-13
Staging Procedures to Diagnose Malignant Pleural Mesothelioma
Mayo Clinic
Terminated
NCT03717415 2024-12-27
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Phase 1/2 Terminated
NCT06034860 2024-11-01
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
Phase 1 Terminated
NCT02748798 2024-10-15
Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
Thunder Bay Regional Health Research Institute
Phase EARLY_PHASE1 Terminated
NCT02714374 2024-08-06
GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers
University of California, San Diego
Phase 1 Terminated
NCT02613312 2024-07-30
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
Mayo Clinic
Terminated
NCT03685591 2024-06-26
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT03319537 2024-05-23
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT01898156 2024-04-25
Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer
Kyowa Kirin Co., Ltd.
Phase 1/2 Terminated
NCT02004028 2024-02-20
Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
Verastem, Inc.
Phase 2 Terminated
NCT04840615 2024-02-02
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT03926143 2023-08-04
A Clinical Study of Anetumab Ravtansine in Adults With Solid Tumors Who Have Been Treated in Previous Bayer-sponsored Anetumab Ravtansine Studies
Bayer
Phase 2 Terminated
NCT02688166 2022-10-13
Cardiac MRI Biomarker Testing (GCC 1618)
University of Maryland, Baltimore
Terminated
NCT00637624 2022-08-25
NAC-PNP
Rijnstate Hospital
Phase NA Terminated
NCT02385812 2022-05-18
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
University of Calgary
Phase 2 Terminated
NCT03655821 2022-05-13
IMPROVE-II
Radboud University Medical Center
Phase 4 Terminated
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02838745 2022-03-31
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
Baylor College of Medicine
Phase 1 Terminated
NCT02464904 2022-02-09
Intrapleural Cryotherapy for Malignant Pleural Mesothelioma
Mayo Clinic
Phase NA Terminated
NCT02628535 2022-02-08
Safety Study of MGD009 in B7-H3-expressing Tumors
MacroGenics
Phase 1 Terminated
NCT03644550 2021-12-02
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT03277352 2021-07-22
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT01624090 2019-12-30
Mithramycin for Lung, Esophagus, and Other Chest Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01413451 2019-12-17
Amatuximab for High Mesothelin Cancers
National Institutes of Health Clinical Center (CC)
Phase EARLY_PHASE1 Terminated
NCT00094978 2019-12-12
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01258868 2019-12-03
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT03436732 2019-11-22
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02062632 2019-10-01
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Mayo Clinic
Phase 2 Terminated
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated
NCT01445392 2018-08-03
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01188486 2018-04-17
Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
Stanford University
Phase NA Terminated
NCT01604005 2018-01-29
PIT
The Christie NHS Foundation Trust
Phase 3 Terminated
NCT00895648 2017-05-04
Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
University Health Network, Toronto
Phase 2 Terminated
NCT00604461 2017-03-23
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Terminated
NCT00597116 2016-10-10
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Sanofi
Phase 2 Terminated
NCT01770665 2016-09-16
MiCK Assay
Pierian Biosciences
Terminated